Last reviewed · How we verify
NCT05767645: TRIBUTE
Mistral Percutaneous Tricuspid Valve Durable Repair Pivotal Study
NA trial testing Mistral Procedure in Tricuspid Valve Regurgitation in 75 participants. Status unknown.
1 March 2024
Quick facts
| Lead sponsor | Mitralix |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 21 June 2021 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Mistral Procedure
Conditions studied
- Tricuspid Valve Regurgitation — all drugs for Tricuspid Valve Regurgitation →
Sponsor
Mitralix
Who can join
18 and older, any sex, with Tricuspid Valve Regurgitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR). The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Current Landscape of Transcatheter Tricuspid Valve Intervention.
Seligman H, Vora AN, Haroian NQ, Puri R, et al · · 2023 · cited 10× · PMID 39131057 · DOI 10.1016/j.jscai.2023.101201 -
Transcatheter Management of Tricuspid Regurgitation: A Review of Contemporary Evidence.
Sammour YM, Anwaar MF, Cabral-Amador F, Garcia J, et al · · 2024 · cited 3× · PMID 39885934 · DOI 10.17925/hi.2024.18.2.4
Verify or expand the search:
- PubMed search for NCT05767645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tricuspid Valve Regurgitation
Currently open trials in the same condition.
- NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
- NCT06611579 — Clinical Study of the inQB8 TTVR System · NA · recruiting
- NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
- NCT06581471 — The TRICURE EU Pivotal Study · NA · recruiting
- NCT07342036 — Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion · recruiting
Other Mitralix trials
Trials by the same sponsor.
- NCT04073979 — MATTERS II - Mistral Percutaneous Tricuspid Valve Repair FIM Study · NA · completed
- NCT04071652 — MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05767645 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mitralix
- Last refreshed: 15 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05767645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing